As of November 6, 2026, Mineralys Therapeutics, Inc. is a publicly traded company (Nasdaq: MLYS). The largest holder reporting an active stake on Schedule 13D is RA Capital, at 9.9%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Catalys Pacific Fund, LP (10.1%), BlackRock (5.2%), Fidelity (FMR) (5.1%) (Schedule 13D/A, September 8, 2025).
Is this your company?
About to sign with, pay or invest in Mineralys Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Mineralys Therapeutics, Inc. a real, registered company?
- Mineralys Therapeutics, Inc. files with the SEC under CIK 1933414 (its SEC filings).
- Its shares are listed under the ticker MLYS on Nasdaq (SEC company record).
- business address in Radnor, Pennsylvania, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under MINERALYS THERAPEUTICS INC in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Kristine Peterson, Director (Form 8-K filed 2026-10-19). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Fidelity (FMR) (filed 2026-08-06).
Who are Mineralys Therapeutics, Inc.'s owners and officers?
Mineralys Therapeutics, Inc.: business address in Radnor, Pennsylvania; industry Pharmaceutical Preparations (Form D, 2026-10-19).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-06 | Fmr LLC | 5.1% |
| Schedule 13G/A, 2026-02-13 | Catalys Pacific Fund, LP | 10.1% |
| Schedule 13G, 2026-02-05 | Fmr LLC | 6.3% |
| Schedule 13G, 2026-01-21 | Blackrock, Inc. | 5.2% |
| Schedule 13D/A, 2025-09-08 | Ra Capital Management, L.P. | 9.9% |
| Schedule 13D/A, 2025-09-08 | Samsara Biocapital, L.P. | 8.2% |
| Schedule 13G/A, 2025-08-14 | Catalys Pacific Fund, LP | 13.5% |
| Schedule 13G/A, 2025-08-14 | Andera Partners | 4.2% |
Questions about who owns Mineralys Therapeutics, Inc.
Who owns Mineralys Therapeutics, Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of Mineralys Therapeutics, Inc.: Catalys Pacific Fund, LP (10.1%, Schedule 13G/A, filed 2026-02-13), Ra Capital Management, L.P. (9.9%, Schedule 13D/A, filed 2025-09-08), Samsara Biocapital, L.P. (8.2%, Schedule 13D/A, filed 2025-09-08), Blackrock, Inc. (5.2%, Schedule 13G, filed 2026-01-21) and Fmr LLC (5.1%, Schedule 13G/A, filed 2026-08-06).
Who are the largest shareholders of Mineralys Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Mineralys Therapeutics, Inc. on this page are Catalys Pacific Fund, LP (10.1%), Ra Capital Management, L.P. (9.9%) and Samsara Biocapital, L.P. (8.2%).
When did Catalys Pacific Fund, LP buy into Mineralys Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Catalys Pacific Fund, LP on this page is the Schedule 13G/A, filed 2025-08-14, reporting 13.5%; its latest, Schedule 13G/A filed 2026-02-13, reports 10.1%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 8 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Mineralys Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Mineralys Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Mineralys Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-10-19 | Kristine Peterson | Director | appointed | 2026-10-19 |
| Form 8-K, 2026-10-19 | Lonnel Coats | Director | appointed |
Which insiders own Mineralys Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- Catalys Pacific Fund, LP, a 10% owner: 7,903,838 shares (8.9% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-11-21).
- , a director: 7,805,718 shares (8.8% of shares outstanding), held indirectly (the form names the holder only in its footnotes) (Form 4, 2026-09-24).
- , a director and 10% owner: 5,877,218 shares (6.6% of shares outstanding), 6,200 held directly and 5,871,018 indirectly (Form 4, 2026-02-20).
- RA Capital Healthcare Fund LP, a director: 5,825,521 shares (6.6% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-03-31).
- RA Capital Nexus Fund III, L.P., a director: 5,825,521 shares (6.6% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-03-31).
Shares outstanding: 88,557,097 as of 2026-10-29, from the company's latest SEC cover page.
How much has Mineralys Therapeutics, Inc. raised?
No fundraising or offering filing from Mineralys Therapeutics, Inc. is on file with us.
Keep reading
More on Mineralys Therapeutics, Inc. and the records around it.
Mineralys Therapeutics, Inc. elsewhere on the record
- Leadership changes Aug 2026
- 5%+ stake filings Aug 2026
Companies that share a holder
- Andera Partners also filed stake reports on 2 other companies: Inventiva S.A. (Oct 2026), EVOMMUNE, INC. (Aug 2026)
- Samsara BioCapital, L.P. also filed stake reports on 14 other companies: PMV Pharmaceuticals, Inc. (Sep 2026), Eloxx Pharmaceuticals, Inc. (Aug 2026), RANI THERAPEUTICS HOLDINGS, INC. (May 2026)
- RA Capital Management, L.P. also filed stake reports on 100 other companies: Climb Bio, Inc. (Nov 2026), Bambusa Therapeutics, Inc. (Nov 2026), SOLID BIOSCIENCES INC. (Nov 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/mineralys-therapeutics